Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT05080712
Recruiting Observational

Progression of Atrial Fibrillation in the Young

NCT05080712 · tracked via the Priya Life Science Sweden tracker
Sponsor
Karolinska Institutet
Phase
Observational
Started
2021-09-25
Last updated
2024-05-23

Condition(s) studied

Atrial Fibrillation

Study summary

The purpose of this study is to investigate the presence and magnitude of structural changes of the heart and their long-term development in young patients with atrial Fibrillation (AF), studied by echocardiographic measurements and plasma biomarkers and their association to AF burden, studied using long-term ECG

Eligibility

Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria: * Atrial fibrillation * Diagnosis of atrial fibrillation within one year of inclusion Exclusion Criteria: * Duration of atrial fibrillation over one year. * Acute stressor for atrial fibrillation such as: acute ischemic heart disease or infection

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Danderyd Hospital Stockholm Sweden Recruiting

More Karolinska Institutet trials in Sweden

Sensory Neurography and S2PD, a Test-Retest Study Active, not recruiting
Diagnostic and Prognostic Salivary Biomarkers in Chronic Muscle Pain Active, not recruiting
Brain Connectivity Marker for Alzheimer's Disease Recruiting
Feasibility, Acceptability, and Preliminary Effects of ISTDP for Personality Disorders in a Specialized Psychiatric Clinic Enrolling by invitation
Health-related Quality of Life in Chiari Malformation Type 1 - A National Cross-Sectional Patient Survey Enrolling by invitation

Other trials for the same condition

Ablation of Fibrotic Areas in Patients With Persistent Atrial Fibrillation. Active, not recruiting
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress Recruiting
Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation Recruiting
Prevention of Stroke by Left Atrial Appendage Closure in Atrial Fibrillation Patients After Intracerebral Hemorrhage Active, not recruiting
The Study of Men Born in 1943 Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05080712 on ClinicalTrials.gov ↗ ← All trials in Sweden